Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
103 hedge funds and large institutions have $622M invested in Dicerna Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 19 reducing their positions, and 13 closing their positions.
13,200% more call options, than puts
Call options by funds: $133K | Put options by funds: $1K
163% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 19
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
8% more funds holding
Funds holding: 95 → 103 (+8)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
26% less capital invested
Capital invested by funds: $838M → $622M (-$216M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.89M |
| 4 |
RI
RTW Investments
New York
|
+$5.87M |
| 5 |
SCM
Sio Capital Management
New York
|
+$5.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.4M |
| 2 |
BM
Bridger Management
New York
|
-$9.95M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.39M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.66M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.53M |
DRNA Hedge Fund Activity: Q4 2018 in Review
103 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2018, worth a combined $622M — down 26% from $838M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new DRNA positions and 13 closed out — a net gain of 9 holders — while 50 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $17.9M. The largest seller was RA Capital Management, cutting an estimated $19.4M.
- 103 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2018, up from 95 in Q3 2018.
- Funds reported $622M of Dicerna Pharmaceuticals, Inc. stock for Q4 2018, down 26% quarter-over-quarter.
- 22 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2018 and 13 closed out, a net change of +9 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2018 was BlackRock, an estimated $17.9M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2018 was RA Capital Management, an estimated $19.4M sold.
Based on aggregated 13F filings for Q4 2018.